NanoMedicine Labs
NanoMedicine Labs Raises $460M Series C to Transform Healthcare
Quick Facts
NanoMedicine Labs
Breakthrough nanoscale drug delivery systems enabling targeted cancer treatment with 95% reduced side effects.
About the Funding
NanoMedicine Labs has successfully raised $460M in a Series C funding round, bringing their total valuation to $5.8B. This significant investment will fuel the company's mission to advance phase iii clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases.
Use of Funds
Advance Phase III clinical trials, scale manufacturing capabilities, and expand pipeline to rare diseases
Company Overview
Breakthrough nanoscale drug delivery systems enabling targeted cancer treatment with 95% reduced side effects.
Key Investors
- • Johnson & Johnson Innovation
- • Roche Ventures
- • RA Capital
- • Flagship Pioneering
Founders
- • Dr. Jennifer Liu
- • Dr. Robert Kim
Previous Rounds
Market Impact
This funding round positions NanoMedicine Labs as a leader in the Biotech space, with the capital to accelerate innovation and expand their market presence. The investment reflects growing confidence in healthcare solutions and the company's potential to transform the industry.
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...